Closely-held Soricimed Biopharma has named Bob Cory as VP of business development and appointed Tom Reeves, a director, as chairman.
Dr. Cory has over 20 years of business and corporate development leadership experience in the biopharmaceutical industry. Most recently, he was VP of business development with Qu Biologics. Mr. Reeves currently is president and CEO of closely-held Interface Biologics.
Soricimed recently completed a Phase 1 trial of its first-in-class peptide, SOR-C13, in advanced solid tumor cancers – the first drug candidate targeting calcium channel TRPV6 to have entered clinical development. Top-line results will be reported in the current quarter.
In a statement, Paul Gunn, president and CEO, said Dr. Cory’s expertise will be “invaluable at this stage of our organization.
